VERA Vera Therapeutics Inc
Company Analysis
Latest News
🔴 Vera Therapeutics is trading 4.1% down today on profit-taking after its recent FDA-driven rally
Vera Therapeutics is trading 4.1% down at $40.76 as the stock undergoes consolidation following a significant rally earlier in July. • The stock's recent...
🟢 Vera Therapeutics is trading 4% up today following recent FDA approval of its IgA nephropathy drug
Vera Therapeutics is trading 4% up at $43.16 as momentum continues from the recent FDA accelerated approval of its IgA nephropathy drug, atacicept...
Vera Therapeutics downgraded to Sell, facing stiff competition for TRUTAKNA
Analysts downgraded Vera Therapeutics from Hold to Sell following the FDA's accelerated approval of its IgAN treatment, TRUTAKNA. The report cites a crowded...
🔴 Vera Therapeutics is trading 5.4% down today on profit-taking after TRUTAKNA FDA approval
Vera Therapeutics is trading 5.38% down today at $40.16 following a sharp post-approval pullback as investors lock in gains. • The decline is characterized as...
🔴 VERA is trading 4.9% down today on profit-taking following its FDA approval rally
VERA is trading at $40.86 (4.9% down) as investors take profits following a sharp rally sparked by the FDA’s accelerated approval of its IgA nephropathy drug,...
🔴 VERA is trading 4.6% down today on profit-taking after FDA approval surge
VERA is trading at $41.00 (4.6% down) in pre-market as investors lock in gains following the FDA's accelerated approval of its IgA nephropathy drug, atacicept...
🟢 VERA is trading 5% up today as investors position ahead of FDA decision on atacicept
VERA is trading 5% up at $42.14 as investors position ahead of a key FDA decision for its IgA nephropathy treatment, atacicept. • The Biologics License...
🟢 VERA is trading 4.8% up today ahead of FDA PDUFA date for atacicept
VERA is trading 4.8% up at $42.04 as traders position ahead of the FDA’s PDUFA action date for its IgA nephropathy drug, atacicept. - The Biologics License...
🟢 VERA is trading 5.5% up today ahead of pivotal FDA action date for atacicept
VERA is trading 5.5% up today at $41.90 in pre-market action as traders position ahead of a pivotal FDA action date for its lead IgA nephropathy drug,...
🔴 VERA makes sharp 12.1% drop
VERA is trading at $37.51, down 12.1% versus the comparison close of $42.66 during regular trading. This is a price-movement alert; no separate...
🔴 VERA is trading 5.7% down today after no clear company-specific catalyst
VERA is trading at 5.7% down now at $40.22 after no clear company-specific catalyst surfaced in the available news flow. The stock’s move appears consistent...
🟢 VERA is trading 5.7% up today, extending a multi-day rally on atacicept optimism
VERA is trading 5.7% up at $44.88 in pre-market, extending a strong multi-day rally fueled by ongoing positive sentiment around its lead drug, atacicept. •...
🟢 VERA extends move to 5.3% up
VERA is trading at $42.65, up 5.3% versus the comparison close of $40.50 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Vera Therapeutics Inc is trading 4.33% up
VERA is trading at $42.26, up 4.33%.